Fenofibrate

Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Product Specifications

CAS Number

[49562-28-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Cytochrome P450; PPAR

Type

Reference compound

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-anti-virus

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Fenofibrate.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C(OC(C)C)=O

Molecular Formula

C20H21ClO4

Molecular Weight

360.83

Precautions

H302, H315, H319, H335

References & Citations

[1]Schelleman H, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78 (3) :639-48.|[2]Gong Y, et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Sep 30. pii: S2352-3964 (16) 30448-0.